G. Alimena
About
In The Last Decade
G. Alimena
31 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Hematology 1.3k
- Genetics 832
- Rheumatology 409
- Molecular Biology 331
- Oncology 305
Countries citing papers authored by G. Alimena
This map shows the geographic impact of G. Alimena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Alimena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Alimena more than expected).
Fields of papers citing papers by G. Alimena
This network shows the impact of papers produced by G. Alimena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Alimena. The network helps show where G. Alimena may publish in the future.
Co-authorship network of co-authors of G. Alimena
This figure shows the co-authorship network connecting the top 25 collaborators of G. Alimena. A scholar is included among the top collaborators of G. Alimena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Alimena. G. Alimena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 54 | |
| 2 | 40 | |
| 3 | 59 | |
| 4 | 57 | |
| 5 | A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. | 8 |
| 6 | A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group breakdown → | 518 |
| 7 | 9 | |
| 8 | Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. | 75 |
| 9 | Recent advances in biological and therapeutic aspects of myeloproliferative disorders. | 3 |
| 10 | 13 | |
| 11 | Long-term remission of T-lymphoid extramedullary blast crisis of chronic myelogenous leukemia following allogeneic bone marrow transplantation. | 5 |
| 12 | Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment for CML may necessitate delay in harvesting marrow cells for autografting. | 16 |
| 13 | 147 | |
| 14 | 102 | |
| 15 | 29 | |
| 16 | 60 | |
| 17 | 2 | |
| 18 | 47 | |
| 19 | Retrospective diagnosis of a Fanconi's anemia patient by dyepoxybutane (DEB) test results in parents. | 8 |
| 20 | In vitro correction of Fanconi's anemia chromosome instability | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.